Blue Shield of California aims to produce 5 to 10 low-cost generic drugs in its initial effort, and the BCBSA/Civica group hopes that the first will be available by early 2022. (Photo: Shutterstock)

It may sound counter-intuitive, but a group of insurers is partnering with the “public asset” Civica Rx to bring down the cost of prescription drugs by producing generic versions at lower prices.

The New York Times reports that the insurers—the Blue Cross Blue Shield Association and 18 of its member organizations—have pledged $55 million in a partnership agreement with nonprofit Civica Rx “to create cheaper versions of expensive generic drugs for which there is little competition.”

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

More from this author


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.